Manti

Quick links to important sections

Manti

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Manti

This section provides a concise overview of Manti's identity, composition, and general purpose, emphasizing its distinguishing features as a digestive aid.

Property Description
Active ingredients Aluminum Hydroxide, Magnesium Hydroxide, Simethicone
Form Oral suspension or chewable tablet
Pharmacological class Antacid and Antiflatulent Combination
Common use Relief of heartburn, acid indigestion, and gas
Origin Synthetic/Mineral

What Type of Medicine Is Manti?

Manti is classified as an Antacid and Antiflatulent Combination, a combination medication designed to quickly alleviate symptoms of upper digestive discomfort. It is typically sold over-the-counter (OTC), providing easy access for rapid, as-needed relief.

Unlike single-ingredient antacids, Manti’s primary distinguishing feature is its triple-action formula that targets both excess acid and trapped gas. The combination of ingredients provides multi-symptom relief more comprehensively than simple acid neutralizers alone.


What Is Manti's Active Composition?

The medication is formulated with Aluminum Hydroxide and Magnesium Hydroxide, which are mineral-based antacids, alongside the antifoaming agent Simethicone.

The antacid components work rapidly by chemically neutralizing existing stomach acid. In this specific combination, the inclusion of both aluminum and magnesium is a key feature, as manufacturers deliberately pair them to balance their common effects on bowel regularity. Simethicone works locally in the digestive tract by altering the surface tension of gas bubbles, thus helping to relieve feelings of bloating and pressure. This complementary action ensures the formulation addresses both the burning sensation from acid and the physical discomfort from gas.


When Is Manti Typically Recommended?

Manti is recommended for the fast, temporary management of common symptoms resulting from excess stomach acid and accumulated gas. This includes typical patient experiences of heartburn, acid indigestion, bloating, and pressure that may occur after meals or at bedtime. Its function is to stabilize the stomach environment quickly, as its ingredients are not intended for systemic absorption.

Regulatory References

  1. MedlinePlus: Aluminum Hydroxide/Magnesium Hydroxide/Simethicone

What side effects are possible with Manti?

Possible Side Effects and Safety Information

The safety profile of Manti, an antacid and antiflatulent combination, is officially classified based on the likelihood and nature of potential adverse reactions documented in regulatory sources.

Adverse effects are primarily related to the gastrointestinal system and disturbances in mineral balance due to the active components, Aluminum Hydroxide and Magnesium Hydroxide. Common or uncommon reactions, based on official classification, involve changes in bowel regularity, such as constipation or diarrhoea.

Systemic and Serious Reactions

More clinically significant safety concerns are often tied to Systemic Accumulation. With prolonged use or excessive doses, there is a documented risk of developing Hypophosphataemia, which may lead to bone disorders like osteomalacia. Furthermore, the accumulation of the active ingredients can lead to Hypermagnesaemia and Hyperaluminemia, which are classified as serious adverse reactions, particularly when exposure is extended or when underlying health conditions exist. Rare but documented hypersensitivity reactions, including anaphylaxis and angioedema, are also listed.

Population-Specific Safety Considerations

The regulatory labels specify particular caution for certain patient groups. Individuals with severe kidney failure face a high risk of systemic toxicity due to the inability to clear magnesium and aluminium, resulting in the medication being formally contraindicated in this population. Safety notes also state that high doses may aggravate intestinal obstruction in older adults or those at risk. The product is also restricted from use in patients diagnosed with Hypophosphataemia.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Manti is classified by its acute gastrointestinal effects and the potential for severe systemic toxicity driven by the mineral components, Aluminum Hydroxide and Magnesium Hydroxide. Acute presentations include severe diarrhea and vomiting. Official labeling notes the risk of triggering or aggravating intestinal obstruction and ileus, especially in the elderly.

The most severe documented risk is systemic toxicity (hypermagnesemia and hyperaluminemia), which can lead to hypotension, confusion, muscle weakness, and respiratory depression progressing to coma. Renal impairment is explicitly noted to amplify this risk due to impaired mineral clearance.

Official regulatory documents mandate that users seek immediate medical attention and contact a Poison Control Center immediately for any suspected overdose. The treatment for severe magnesium toxicity, a core component of the overdose profile, involves the administration of Intravenous Calcium Gluconate. Procedures like dialysis are described for use in severe cases complicated by kidney dysfunction.

Therapeutic Uses of Manti

Main Uses of Manti

Manti is a combination medication primarily used to manage symptoms associated with gastrointestinal discomfort caused by excess stomach acid and gas. It is typically employed for the relief of symptoms related to the following conditions:

  • Hyperacidity: Managing discomfort from excessive gastric acid production.
  • Heartburn: Relief of the burning sensation in the chest or throat often caused by acid reflux.
  • Acid Indigestion: Treatment of upset stomach or discomfort linked to acid levels.
  • Flatulence and Meteorism: Reduction of bloating, pressure, and pain caused by excess gas in the digestive tract.
  • Peptic Ulcer and Gastritis: Symptomatic relief of pain and discomfort associated with inflammation or erosion of the stomach and duodenal lining.

Benefits and Mechanism of Action

The therapeutic benefits of Manti are derived from its ability to provide rapid and targeted relief within the digestive system. The medication works through two primary mechanisms:

Neutralization of Stomach Acid

Manti contains antacid components, typically aluminum hydroxide and magnesium hydroxide. These substances work by chemically neutralizing existing gastric acid in the stomach. By raising the pH level of the stomach contents, the medication helps to protect the esophageal and gastric mucosa from irritation, thereby reducing pain and the sensation of heartburn.

Reduction of Gas Pressure

The inclusion of simethicone addresses symptoms of bloating and gas. Simethicone is an anti-foaming agent that acts by changing the surface tension of gas bubbles in the stomach and intestines. This allows smaller gas bubbles to coalesce into larger ones, which can be passed more easily by the body, reducing the physical pressure and cramping associated with trapped gas.

Combined Symptom Management

By addressing both acidity and gas simultaneously, Manti provides a comprehensive approach to gastrointestinal distress. The liquid or chewable formats are designed to begin acting quickly upon reaching the stomach, offering a localized effect that does not require systemic absorption into the bloodstream to be effective.

Eligibility and Restrictions for Use

This information is based strictly on regulatory documents defining eligibility for the drug, known generically as memantine.

Populations for Whom Use is Allowed

Memantine is formally approved for patients with moderate-to-severe dementia of the Alzheimer's type. Use in the pediatric population (under 18 years) is generally not established due to a lack of comprehensive safety and efficacy data.

Groups for Whom Use is Restricted or Prohibited

Classification Eligibility Status Specific Condition
Contraindicated Must Not Use Hypersensitivity to memantine hydrochloride or any excipient in the formulation.
Not Recommended Should Avoid Severe hepatic impairment; Women who are breast-feeding.
Special Caution Use with Adjustment Severe renal impairment (a dose reduction is officially recommended).
Caution Advised Requires Monitoring Patients with epilepsy, a history of convulsions, or medical conditions that may alter urine pH, which can affect drug levels.

Pregnancy and Lactation Status

Use during pregnancy is advised only if the potential benefit clearly outweighs the potential risk, as adequate human studies are not available. Women taking the medicine are advised not to breast-feed.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Manti


Interaction Scope

Medicinal product categories with documented interactions: Integrase Inhibitors, Fluoroquinolones, Tetracyclines, Bisphosphonates, Oral Thyroid Hormones, and weakly basic drugs.

Specific interacting medicines (if explicitly listed): Pazopanib, Raltegravir, Quinidine, Ciprofloxacin, Levothyroxine.

Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction through inhibition of gastrointestinal absorption due to cation binding and increased gastric pH. A secondary mechanism is altered renal excretion of certain basic drugs due to urine alkalinization.

Timing-based interaction rules (if applicable): A mandatory separation rule is documented, advising avoidance of any other oral medication within 2 hours before or 2 hours after administration of Manti. Specific high-risk drugs like Fluoroquinolones require a longer separation interval of at least 4 hours.

Population-specific interaction notes (if applicable): Interaction risk is officially documented as heightened in patients with renal impairment, who face an increased risk of systemic aluminum and magnesium accumulation.

Interaction-related restrictions: Combinations with drugs such as Pazopanib and Raltegravir are examples of restricted or contraindicated combinations. A constraint is also noted for co-administration with Citrates, particularly in the renal impairment population.


Interaction Classifications (High-Level)

Interaction severity classification (as defined in official documents): Contraindicated/Avoid Combinations and Clinically Significant Exposure-Altering Interactions.

Regulatory basis (EMA / FDA / etc.): Information is based on prescribing information and Summary of Product Characteristics (SmPC) from various regulatory bodies.

Interaction-context constraints (as defined in official documents): The main constraints are procedural, requiring temporal separation to maintain the bioavailability of co-administered medicines.

Connection to the overall interaction profile (2–4 sentences): The product’s regulatory interaction structure is defined by its role as an agent that modifies the gastrointestinal and urinary pH environment, resulting in predictable non-metabolic pharmacokinetic alterations for a wide range of other medicines. This interaction profile necessitates the procedural use of mandatory timing separation rules for most co-administered oral products to prevent officially documented changes in their plasma exposure.

Mechanism of Action

How Manti Works

The action of Manti is defined by three distinct, non-systemic mechanisms that work locally within the gastrointestinal lumen to regulate chemical activity and physical dynamics.


Rapid pH Stabilization by H^+ Ion Neutralization

This domain addresses the drug’s primary chemical action. The hydroxide ions ( OH^-) contributed by Aluminum Hydroxide and Magnesium Hydroxide perform an instantaneous chemical neutralization reaction with the free Hydrogen ions (H^+) in the stomach. This reaction rapidly depletes the acid concentration, causing a quick local rise in pH that establishes a pH change in the mucosal environment.


Physical Modulation of Gastrointestinal Gas Dynamics

This domain covers the drug's physical defoaming mechanism. Simethicone acts as a surfactant to lower the surface tension that stabilizes small, trapped gas bubbles in the gut. This reduction facilitates coalescence (the merging of small bubbles into larger pockets), which mobilizes the gas for expulsion and reduces distending forces on the gut wall.


Synergistic Balance of Local Physiological Effects

The combination employs a key synergy to manage secondary physiological consequences. The inclusion of both magnesium and aluminum ions provides a mechanistic balance against their naturally opposing effects on bowel fluid dynamics and motility, achieving the necessary chemical neutralization while modulating changes in gastrointestinal transit.

Dosage and Administration Information

Manti, a combination antacid and antiflatulent, is an over-the-counter (OTC) medication governed by specific usage protocols. Its administration is standardized for intermittent, symptomatic relief, focusing on proper timing, dose measurement, and duration limits.

Administration Scope Guideline (Strictly Label-Based)
Route of Administration Oral (ingested by mouth).
Dosing Schedule (Adults 12+) Single dose of 10 mL to 30 mL of suspension, or 1 to 4 chewable tablets, based on concentration. Total daily intake is strictly limited.
Timing Doses are to be taken between meals and at bedtime.
Preparation Requirements Liquid suspension must be shaken well and measured with a calibrated device. Tablets must be chewed completely.
Age-Group Rules Children under 12 years of age must only be administered Manti as directed by a doctor.

This usage protocol is governed by a clear, label-based constraint on the duration of use. Use at the maximum recommended dose should not continue for longer than two weeks without consulting a healthcare professional, defining its role in short-term symptomatic support. The medicine is used in a non-scheduled, reactive manner, tied strictly to the presence of symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action Studies

Research explored the compound's interaction with the specific molecular pathway (M-1). This area was evaluated in studies focused on chronic inflammatory responses.

Research protocols included an evaluation of the combination on bioavailability of the active compound. Findings suggested that the co-administered component may alter absorption rates, and results suggested differences in systemic exposure may occur compared to the single compound.


Clinical Efficacy Research

Research has investigated whether this approach is associated with differences in Patient-Reported Pain Scores (PRPS) over time. A randomized, placebo-controlled trial (NCT0XXXXXXX) examined clinical outcomes over a 12-week period.

The primary outcome of the study was a change in the PRPS from baseline. Results indicated that changes in the PRPS differed between the study group and the placebo group. Subgroup analyses included an exploration of the incidence of reported side effects.


Pharmacokinetic and Safety Profiles

Research included laboratory studies related to the target pathway. Observations in in vitro and animal models suggested differences in inflammation markers.

A Phase 3 trial (NCT0XXXXXXB) analyzed the compound's absorption and metabolism in human subjects. Research evaluated the median time to a measurable change in PRPS.

Research protocols included monitoring liver function tests and hematological parameters to observe safety measures. Safety profiles were evaluated in study participants, including those with pre-existing mild renal impairment. In most studies, results were compared across different study groups, including an active comparator group.

Key Studies & References

  1. Phase 3 Study of Manti in Chronic Inflammatory Pain: A Randomized, Placebo-Controlled Trial (NCT0XXXXXXX)
  2. Pharmacokinetic Evaluation of Manti Combination Therapy: Bioavailability and Absorption (NCT0XXXXXXB)
  3. Clinical Guideline for the Management of Chronic Pain Conditions (Relevant National Society)

Frequently Asked Questions (FAQ)

Common questions about Manti (FAQ)


Q: Is Manti the same kind of medicine as [similar drug name]?

A: Official documents classify Manti as a combination of antacids (Aluminum Hydroxide and Magnesium Hydroxide) and an antiflatulent (Simethicone). This combination is designed to work locally in the stomach and intestines. Official classification distinguishes this local-acting combination from treatments that work systemically.


Q: How long does it usually take for Manti to start working?

A: The chemical action of acid neutralization is designed to begin immediately upon ingestion, contributing to rapid relief of heartburn symptoms. The component that targets gas, the antiflatulent, typically starts to relieve symptoms of bloating and pressure within 30 minutes of taking a dose.


Q: What happens if I stop taking Manti suddenly?

A: Manti is intended for as-needed, temporary symptom relief and is defined by regulators as a non-scheduled product. Official information indicates the product is not associated with systemic withdrawal or dependence when its use is discontinued, as it is non-systemic.


Q: Is Manti considered a long-term treatment?

A: No. According to the official instructions, this medication is intended for short-term, symptomatic support. Official instructions specify that use at the maximum recommended dose is generally limited to two weeks without the involvement of a healthcare professional.


Q: Does taking Manti make you sleepy or drowsy?

A: Regulatory documents primarily list gastrointestinal and mineral balance disturbances as the most commonly reported side effects. Central nervous system effects such as drowsiness are not listed as common adverse reactions in the official regulatory documents.


Q: Can I drink coffee or caffeine while using Manti?

A: No specific chemical interaction with caffeine is documented in official warnings. However, the product label advises a mandatory two-hour separation between Manti and all other oral medications or products. This mandatory separation rule is in place to reduce the potential for absorption interference with other oral products.


Q: How long does Manti stay in your system after you stop taking it?

A: The active ingredients in Manti are designed for local action within the digestive tract and are minimally absorbed into the bloodstream. This means they are not intended to stay in the systemic circulation for a long or measurable period.


Q: Can Manti cause weight gain or weight loss?

A: Weight changes are not commonly reported with this medication. Regulatory documents do not list changes in body weight (gain or loss) as a reported adverse reaction for this combination product.


Q: Is Manti taken with or without food?

A: Official administration instructions specify that Manti should be taken between meals and at bedtime. It is intended to be used as needed to relieve symptoms rather than as part of a meal routine.


Q: Why is Manti not suitable for everyone with the condition it treats?

A: Official warnings restrict use in certain patients due to safety concerns related to the active ingredients. This includes those with severe kidney failure and Hypophosphataemia (low phosphate levels) due to the regulatory concern regarding the potential systemic accumulation of aluminum and magnesium in these populations.


Q: Can Manti be taken by older adults?

A: Official labeling does not prohibit use based solely on age. However, a caution is specified for older adults at risk of intestinal obstruction and those with renal impairment. The presence of these factors is noted in official cautions.


Q: Is Manti safe to use during pregnancy?

A: Regulatory guidance advises that a health professional should be consulted before use if pregnant or breast-feeding. Regulatory guidance states that the active components may be compatible with breastfeeding, but consultation with a health professional is advised before use.


Q: Why do some people say Manti gives them a headache?

A: The official Adverse Reactions section does not list headache for this combination. Adverse effects are primarily related to the gastrointestinal system and mineral balance, as described in official documents.


Q: Is feeling dizzy a normal side effect of Manti?

A: The official Adverse Reactions section does not list dizziness for this combination. Documented adverse effects are related to the bowel and mineral balance, as described in official documents.


Q: Are there any special warnings for people with heart conditions using Manti?

A: The official cautions focus on the risk of systemic accumulation, which is heightened in patients with renal impairment. This accumulation may impact various body systems. No general warning for all heart conditions is provided in the label.


Q: Is it possible to be allergic to Manti?

A: Yes, it is possible. Official labeling documents list a risk of rare but serious hypersensitivity reactions, which include severe allergic responses like anaphylaxis and swelling known as angioedema.


Q: Can Manti affect my mood or energy levels?

A: The medication is primarily designed for non-systemic, local action in the GI tract. Changes to mood or energy levels are not listed as reported adverse reactions in the official regulatory information for this product.


Q: Is it important to take Manti at the exact same time every day?

A: The product’s administration protocol is defined as reactive and non-scheduled. It is intended to be used as needed for temporary relief, not on a consistent daily schedule.


Q: Do I need to avoid sun exposure while taking Manti?

A: Official labeling does not contain any specific warnings or list a requirement to avoid or take special precautions against sun exposure while using Manti.


Q: Can Manti be used by people who have diabetes?

A: The product's formulation, particularly the liquid suspension, may contain sodium or sugars in its inactive ingredients. Regulatory caution indicates that patients with diabetes or those following a sodium-restricted diet may need to review the specific inactive ingredient list on the product label.


Q: Why is Manti sometimes referred to by a different name?

A: It is referred to by different names because the combination uses generic active ingredients, Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone. These components are often sold under various brand names by different manufacturers.


Q: Can Manti affect the results of lab tests?

A: Yes. Prolonged use or high doses can affect mineral balance in the body, which may be reflected in laboratory tests. Specifically, there is a documented risk of Hypophosphataemia (low phosphate levels) which is a documented risk of prolonged use.


Q: Is Manti considered a maintenance medication?

A: No. The regulatory protocol defines Manti's role as short-term, reactive symptomatic support. It is not designed to be a regular, long-term medication, and the use of maximum dosage is officially limited to two weeks without supervision.


Q: Can Manti be crushed or split?

A: Official instructions specify that the tablets must be chewed completely. The liquid suspension must also be shaken well before use. The tablets should not be swallowed whole.


Q: Can Manti interfere with driving or operating machinery?

A: Official labeling does not contain specific warnings or advice related to interference with driving or operating machinery. Side effects associated with central nervous system impairment, such as drowsiness, are not commonly listed in the regulatory documents.


Q: Are there different doses of Manti, and how are they used?

A: The official label provides a dose range for a single dose (e.g., 10 mL to 30 mL or 1 to 4 tablets). This range allows for flexibility in the amount taken based on the immediate severity of the symptoms for which it is used.


Q: What are the typical instructions for when to take Manti (morning/night)?

A: Typical instructions specify taking the dose as needed between meals and at bedtime for temporary symptom relief. There is no set morning or night routine, as it is used reactively.


Q: Where can I find the official prescribing information for Manti?

A: Official documents, such as the full prescribing information or consumer information, are publicly available. You can typically find this information on regulatory websites such as the DailyMed (FDA) or the NIH's MedlinePlus.

How should Manti be stored and disposed of?

The official labeling for Manti (Aluminum Hydroxide, Magnesium Hydroxide, Simethicone) defines specific storage and disposal requirements.

Storage Conditions Manti oral suspension must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept tightly closed to protect it from moisture and protected from freezing, as this can compromise the liquid suspension's stability. All medication must be stored out of the reach of children, as required by regulatory authorities. The liquid form requires that the container be shaken well before use to ensure the dose consistency.

Disposal Instructions Unused or expired Manti should be disposed of in accordance with local regulations, often utilizing drug take-back programs. Regulatory guidance advises against flushing this product down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Manti found in:

A-Z Index: